| Title | Results from RATIONALE 303: A global phase 3 study of tislelizumab (TIS) vs docetaxel (TAX) as second- or third-line therapy for patients with locally advanced or metastatic NSCLC. |
| Authors | Zhou, Caicun Huang, Dingzhi Yu, Xinmin Liu, Yunpeng Fan, Yun Shu, Yongqian Ma, Zhiyong Wang, Ziping Cheng, Ying Wang, Jie Hu, Sheng Liu, Zhihua Dvorkin, Mikhail Poddubskaya, Elena Disel, Umut Akopov, Andrey Ma, Yiyuan Wang, Yan Pan, Zhenyu Yu, Cunjing Rivalland, Gareth |
| Affiliation | Shanghai Pulm Hosp, Shanghai, Peoples R China Tianjin Med Univ Canc Inst & Hosp, Tianjin, Peoples R China Zhejiang Canc Hosp, Hangzhou, Peoples R China China Med Univ, Hosp 1, Shenyang, Peoples R China Jiangsu Prov Hosp, Nanjing, Peoples R China Henan Canc Hosp, Zhengzhou, Peoples R China Peking Univ, Canc Hosp & Inst, Beijing, Peoples R China Jilin Canc Hosp, Changchun, Peoples R China Chinese Acad Med Sci & Peking Union Med Coll, State Key Lab Mol Oncol, Dept Med Oncol, Natl Canc Ctr,Natl Clin Res Ctr Canc,Canc Hosp, Beijing, Peoples R China Hubei Canc Hosp, Wuhan, Peoples R China Jiangxi Canc Hosp, Nanchang, Jiangxi, Peoples R China BHI Omsk Reg Clin Oncol Dispensary, Omsk, Russia VitaMed LLC, Moscow, Russia Acibadem Adana Hosp, Adana, Turkey Pavlov First St Petersburg State Med Univ, St Petersburg, Russia BeiGene Beijing Co Ltd, Beijing, Peoples R China Auckland City Hosp, Auckland, New Zealand |
| Issue Date | Jul-2021 |
| Publisher | CANCER RESEARCH |
| URI | http://hdl.handle.net/20.500.11897/623096 |
| ISSN | 0008-5472 |
| Indexed | SCI(E) |
| Appears in Collections: | 北京肿瘤医院 |
